The DOI matches its Crossref record.
Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women
Abstract
OBJECTIVE: To determine the effects of metformin on blood pressure, left ventricular mass, and some metabolic and endocrine parameters in nondiabetic, obese, hypertensive women. RESEARCH DESIGN AND METHODS: Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. All patients were hospitalized 4 times, i.e., before randomization and after each treatment (metformin or placebo), to conduct metabolic and cardiovascular investigations (oral glucose tolerance test, euglycemic clamp associated with indirect calorimetry, and echocardiography). RESULTS: Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. CONCLUSIONS: These findings suggest that metformin treatment in obese, nondiabetic, hypertensive women produces a more favorable cardiovascular risk profile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoglycemia is very uncommon with metformin monotherapy [173] but has been reported in combination regimens [174], likely due to metformin potentiating other therapeutic agents.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [173]
Citations
Cited by
Sorted by citations
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,393
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 888
Zeng, G., & Quon, M. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118871 · Cited by 726
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567
“Hypoglycemia is very uncommon with metformin monotherapy [173] but has been reported in combination”
BackgroundStettler, C., Allemann, S., Jüni, P., Cull, C. A., Holman, R. R., Egger, M., Krähenbühl, S., & Diem, P. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.015 · Cited by 468
Freemark, M., & Bursey, D. (2001) · PEDIATRICS · doi:10.1542/peds.107.4.e55 · Cited by 436
Cusi, K. J., Consoli, A., & DeFronzo, R. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.11.8923861 · Cited by 463
Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamışlıgil, G. S., et al. (2010) · Diabetes · doi:10.2337/db10-0308 · Cited by 409
“, metformin and thiazolidinediones) (34-41).”
BackgroundDunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Matthaei, S., Stümvoll, M., Kellerer, M., & Häring, H. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 375
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S. L., Nicholls, A. W., Baker, D., Horn, S. V., Thomas, E., Rajpal, D. K., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 293
“In addition, metformin improves the lipid profile [4], restores ovarian function in polycystic ovary syndrome [5], reduces fatty infiltration of the liver [6], and lowers microvascular and macrovascular complications associated with T2DM.”
BackgroundAn Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus
Davidson, M. B., & Peters, A. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00353-1 · Cited by 253
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Howlett, H. C. S., & Bailey, C. J. (1999) · Drug Safety · doi:10.2165/00002018-199920060-00003 · Cited by 201
“[134,135] Metformin has also been shown to improve erythrocyte deformability,[136] and enhance limb blood flow in patients with type 2 diabetes mellitus[39] and during leg plethysmography studies in patients with peripheral vascular disease,[40,41] although claims of lowered blood pressure in some studies[29,30] have…”
BackgroundThe Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease
Haffner, S. M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0343 · Cited by 193
Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., van der Burg, B. B., Donker, A. J. M., & Stehouwer, C. D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2133 · Cited by 177
Can metformin reduce insulin resistance in polycystic ovary syndrome?
Açbay, Ö., & Gündoğdu, S. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58266-1 · Cited by 173
Goodarzi, M. O., & Bryer‐Ash, M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00448.x · Cited by 163
Wang, C., Niederstrasser, H., Douglas, P. M., Lin, R., Jaramillo, J., Li, Y., Oswald, N. W., Zhou, A., McMillan, E. A., Mendiratta, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02332-3 · Cited by 158
Metformin‐associated lactic acidosis: a rare or very rare clinical entity?
Chan, N. N., Brain, H., & Feher, M. D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00006.x · Cited by 139
Agard, C., Rolli‐Derkinderen, M., de la Roque, E. D., Rio, M., Sagan, C., Savineau, J., Loirand, G., & Pacaud, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00445.x · Cited by 124
“Furthermore, metformin is described to have anti-hypertensive properties in hypertensive obese women and in patients with type 2 diabetes (Giugliano et al., 1993).”
BackgroundMetformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
Forouzandeh, F., Salazar, G., Patrushev, N. A., Xiong, S., Hilenski, L. L., Fei, B., & Alexander, R. W. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001202 · Cited by 129
“Also, data from clinical studies confirm a modest effect of metformin on attenuation of blood pressure.(54) However, data are scarce on whether cardiovascular benefits of metformin can be seen in nondiabetic conditions such as in patients with risk factors for CVD in the absence of DM2.”
BackgroundWorldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 122
Metabolic consequences of hyperglycemia and insulin resistance
Jellinger, P. S. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80019-6 · Cited by 121
Treatment of Obesity Hypertension and Diabetes Syndrome
Zanella, M. T., Kohlmann, O., & Ribeiro, A. B. (2001) · Hypertension · doi:10.1161/01.hyp.38.3.705 · Cited by 119
Majithiya, J. B., & Balaraman, R. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.10.020 · Cited by 114
Mittendorfer, B., Horowitz, J. F., DePaoli, A. M., Mccamish, M. A., Patterson, B. W., & Klein, S. (2011) · Diabetes · doi:10.2337/db10-1302 · Cited by 114
“In contrast, current treatment strategies for insulin resistance, such as weight loss and pharmacotherapy, improve insulin-mediated glucose uptake by ;25% or more (13,26,27).”
BackgroundMetformin: a new oral biguanide
Campbell, R. K., White, J. R., & Saulie, B. A. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80017-8 · Cited by 116
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111
Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study
Elder, D. H. J., Singh, J. S. S., Levin, D., Donnelly, L. A., Choy, A.-M., George, J., Struthers, A. D., Doney, A. S. F., & Lang, C. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.455 · Cited by 109
Cho, E. J., Hwang, H. J., Kim, S. W., Oh, J. Y., Baek, Y. M., Choi, J. W., Bae, S. H., & Yun, J. W. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0972-2 · Cited by 111
“Among these, metformin (a biguanide) and thiazolidinediones (TZDs) have proven to be quite useful (Bailey and Turner 1996; Giugliano et al. 1993; Landin et al. 1991; Lee et al. 1994; Verma et al. 1994).”
BackgroundEffect of the anti-diabetic drug metformin on bone mass in ovariectomized rats
Gao, Y., Li, Y., Xue, J., Jia, Y., & Hu, J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.051 · Cited by 105
Metformin as Treatment for Overweight and Obese Adults: A Systematic Review
Levri, K. M. (2005) · The Annals of Family Medicine · doi:10.1370/afm.343 · Cited by 104
Cheng, Y., Leu, H., Chen, T., Chen, C.-L., Kuo, C., Lee, S., & Kao, C.-L. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.09.001 · Cited by 104
Montagnani, M., & Quon, M. J. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00092.x · Cited by 102
Nyane, N. A., Tlaila, T. B., Malefane, T. G., Ndwandwe, D. E., & Owira, P. M. O. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.042 · Cited by 101
Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328333645a · Cited by 103
Manohar, V., Talpur, N. A., Echard, B. W., Lieberman, S., & Preuss, H. G. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00180.x · Cited by 99
Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine
Ikeda, T., Iwata, K., & Murakami, H. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00396-2 · Cited by 97
The triglyceride–high-density lipoprotein axis: An important target of therapy?
Szapary, P. O., & Rader, D. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.037 · Cited by 87
Malin, S. K., Nightingale, J., Choi, S., Chipkin, S. R., & Braun, B. (2013) · Obesity · doi:10.1002/oby.20235 · Cited by 88
“BP is often lowered after exercise training (11), but the effects of metformin are less consistent (13,29-31).”
BackgroundGuðbjörnsdóttir, S., Friberg, P., Elam, M., Attvall, S., Lönnroth, P., & Wallin, B. G. (1994) · Blood Pressure · doi:10.3109/08037059409102293 · Cited by 80
Amador‐Licona, N., Guízar-Mendoza, J., Vargas, E., Sánchez-Camargo, G., & Zamora-Mata, L. (2000) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00241-1 · Cited by 78
Exercise in a Pill: The Latest on Exercise-Mimetics
Guerrieri, D., Moon, H. Y., & van Praag, H. (2016) · Brain Plasticity · doi:10.3233/bpl-160043 · Cited by 80
Metformin: Intrinsic Vasculoprotective Properties
Wiernsperger, N. F. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050025230 · Cited by 75
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Hart, P. C., Chiyoda, T., Liu, X., Weigert, M., Curtis, M., Chiang, C.-Y., Loth, R. M., Lastra, R. R., McGregor, S. M., Locasale, J. W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0409 · Cited by 76
“The biguanide metformin has been shown to affect intracellular and circulating levels of lipids in diabetes (22, 25, 38), metabolic syndrome (39), and cardiovascular disease (40).”
BackgroundChazova, I. E., Almazov, V. A., & Shlyakhto, E. V. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00606.x · Cited by 77
Liang, B., Wang, S., Wang, Q., Zhang, W., Viollet, B., Zhu, Y., & Zou, M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300606 · Cited by 74
Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes · doi:10.2337/db16-0512 · Cited by 68
“, it reduces insulin resistance (2), improves the uptake of glucose in muscle (3,4), reduces the risk for cancer (5), and lowers the values of LDL cholesterol (LDL-C) (6).”
BackgroundPalumbo, P. J. (1998) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(97)00053-6 · Cited by 67
Gómez‐García, A., Torres, G. M., Ortega-Pierres, L. E., Rodríguez-Ayala, E., & Álvarez-Aguilar, C. (2007) · Revista Española de Cardiología · doi:10.1157/13113929 · Cited by 66
Metabolic effects of metformin in patients with impaired glucose tolerance
Lehtovirta, M., Forsén, B., Gullström, M., Häggblom, M. M., Eriksson, J. G., Taskinen, M., & Groop, L. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00539.x · Cited by 67
Han, X., Zhang, F., Meng, L., Xu, Y., Li, Y., Li, A., Turyk, M. E., Yang, R., Wang, P., Zhang, J., et al. (2019) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2019.110125 · Cited by 71
Acute Sympathoinhibitory Actions of Metformin in Spontaneously Hypertensive Rats
Petersen, J. S., & DiBona, G. F. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.619 · Cited by 63
Metformin Therapy in Diabetes: The Role of Cardioprotection
Messaoudi, S. E., Rongen, G. A. P. J. M., & Riksen, N. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0314-z · Cited by 62
“Metformin seems to improve the lipid profile by lowering triglyceride levels, total cholesterol and LDL cholesterol levels, while maintaining or increasing HDL levels [37–42].”
BackgroundInsulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Checa, M. Á., Requena, A., Salvador, C., Tur, R., Callejo, J., Espinós, J. J., Fábregues, F., Herrero, J. C., & (Reproductive Endocrinology Interest Group of the Spanish Society of Fertility) (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi015 · Cited by 60
“Metformin has beneficial effects on serum lipid profiles in obese(Giugliano et al., 1993) and lean patients with non-insulin dependent diabetes mellitus, in other patients with type 2 diabetes and in patients with concomitant type 2 diabetes, hypertension and/or hyperlipidaemia (Landin et al.,…”
BackgroundMetformin: Nonglycemic Effects and Potential Novel Indications
Anabtawi, A., & Miles, J. M. (2016) · Endocrine Practice · doi:10.4158/ep151145.ra · Cited by 58
Charles, M.-A. A., Eschw�ge, E., Grandmottet, P., Isnard, F., Cohen, J., Bensoussan, J.-L., Berche, H., Chapiro, O., Andr�, P., Vague, P., et al. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200001/02)16:1 · Cited by 58
Rao, N. S., Pradeep, A. R., Kumari, M., & Naik, S. B. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.120298 · Cited by 59
“It has also been shown that MF may be helpful in the fight against heart disease, kidney disease, decreased sexual ability and circulation problems.(5) Numerous studies have reported on the effects of this agent on bone turnover.”
BackgroundMoreno-Arriola, E., Hafidi, M. E., Ortega-Cuéllar, D., & Carvajal, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148089 · Cited by 57
“Strikingly, we showed that in wild-type nematodes metformin prevented the effects generated by excess glucose intake, restoring the metabolic markers to control levels; similar to what occurs in obese and diabetic patients, where chronic metformin treatment decreases glucose and lipid levels in plasma [56].”
BackgroundEleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55
“Some studies have shown that metformin reduces fasting plasma total cholesterol, total triglyceride and VLDL cholesterol concentrations and increases HDL cholesterol levels [48-51].”
BackgroundFontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.005 · Cited by 53
Expression pattern of perilipins in human brain during aging and in Alzheimer's disease
Conte, M., Medici, V., Malagoli, D., Chiariello, A., Cirrincione, A., Davin, A., Chikhladze, M., Vasuri, F., Legname, G., Ferrer, I., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12756 · Cited by 53
Bell, P. M., & Hadden, D. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70265-6 · Cited by 52
MARTELL, N., RODRIGUEZ-CERRILLO, M., GROBBEE, D. E., LÓPEZ-EADY, M. D., FERNÁNDEZ-PINILLA, C., AVILA, M., FERNANDEZ-CRUZ, A., & LUQUE, M. (2003) · Blood Pressure · doi:10.1080/08037050310009950 · Cited by 49
“[32] reported similar results in a group of obese, no diabetic hypertensive women.”
ResultA Review on The Protective Effects of Metformin in Sepsis-Induced Organ Failure.
Hassan, F. I., Didari, T., Khan, F., Niaz, K., Mojtahedzadeh, M., & Abdollahi, M. R. (2020) · PubMed Central · doi:10.22074/cellj.2020.6286 · Cited by 48
“Metformin was shown to decrease blood pressure, left ventricular mass, and cholesterol, triglycerides, and fibrinogen levels in obese non-diabetic hypertensive women (41).”
BackgroundInsulin resistance and metformin in polycystic ovary syndrome
Ben‐Haroush, A., Yogev, Y., & Fisch, B. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2003.11.027 · Cited by 47
“In obese, nondiabetic women, metformin was found to decrease plasma cholesterol, triglyceride, and increase HDL-cholesterol concentrations, thereby, improving the lipoprotein profile and possibly reducing cardiovascular risk [67].”
BackgroundShishavan, M. H., Henning, R. H., van Buiten, A., Goris, M., Deelman, L. E., & Buikema, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-11430-7 · Cited by 48
“Some clinical studies have reported a blood pressure lowering effect of metformin [8-10] although others reported the lack of such effects [11-12].”
BackgroundKurian, I. G., Dileep, P., Ipshita, S., & Pradeep, A. R. (2018) · Journal of Investigative and Clinical Dentistry · doi:10.1111/jicd.12324 · Cited by 46
Insulin resistance in hypertension and cardiovascular disease
Lamounier‐Zepter, V., Ehrhart‐Bornstein, M., & Bornstein, S. R. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.002 · Cited by 46
Molusky, M. M., Hsieh, J., Lee, S. X., Ramakrishnan, R., Tascau, L., Haeusler, R. A., Accili, D., & Tall, A. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311212 · Cited by 45
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43
Banek, C. T., Bauer, A. J., Needham, K. W., Dreyer, H. C., & Gilbert, J. S. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00903.2012 · Cited by 41
“Administration of an adenosine mimetics similar to AICAR, such as metformin, have long been recognized to improve cardiovascular function and lower blood pressure in nonpregnant hypertensives (20, 36), but the mechanisms remain uncharacterized (1, 19, 36, 38).”
BackgroundMetformin prevents vascular damage in hypertension through the AMPK/ER stress pathway
Chen, C., Kassan, A., Castañeda, D., Gabani, M. H., Choi, S. K., & Kassan, M. (2019) · Hypertension Research · doi:10.1038/s41440-019-0212-z · Cited by 40
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats
Zhao, J., Li, Y., Zhang, H., Shi, D., Li, Q., Meng, Y., & Zuo, L. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-00989-y · Cited by 40
Determination of Plasma Metformin by a New Cation-Exchange HPLC Technique
Bonfigli, A. R., Manfrini, S., Gregorio, F., Testa, R., Testa, I., Sio, G. D., & Coppa, G. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199906000-00015 · Cited by 40
Dorella, M., Giusto, M., Tos, V. D., Campagnolo, M., Palatini, P., Rossi, G., Ceolotto, G., Felice, M., Semplicini, A., & Prato, S. D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.4.8636369 · Cited by 45
Attenuation of Hypertension by Insulin-Sensitizing Agents
Kotchen, T. A. (1996) · Hypertension · doi:10.1161/01.hyp.28.2.219 · Cited by 38
Metformin Treatment Improves Erectile Function in an Angiotensin II Model of Erectile Dysfunction
Labazi, H., Wynne, B. M., Tostes, R. C., & Webb, R. C. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12245 · Cited by 38
Stakos, D., Schuster, D. P., Sparks, E. A., Wooley, C. F., Osei, K., & Boudoulas, H. (2005) · Heart · doi:10.1136/hrt.2003.027722 · Cited by 39
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37
Uehara, M. H., Kohlmann, N. E. B., Zanella, M. T., & Ferreira, S. R. G. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00136.x · Cited by 38
Ji, S., Wang, L., & Li, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00704 · Cited by 38
“In patients with T2DM, who are also obese, metformin also plays a clinical role in obesity (5, 6).”
BackgroundCardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38
Palamara, K., Mogul, H. R., Peterson, S. J., & Frishman, W. H. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000233903.57946.fd · Cited by 36
Effects of metformin on endothelial health and erectile dysfunction
Patel, J. P., Lee, E. H., Mena, C. I., & Walker, C. N. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.03.52 · Cited by 33
Wulffelé, M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.161311.x · Cited by 33
Grosskopf, I., Ringel, Y., Charach, G., Maharshak, N., Mor, R., Iaina, A., & Weintraub, M. S. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1598 · Cited by 32
Metformin Decreases Blood Pressure and Obesity in OLETF Rats Via Improvement of Insulin Resistance.
Kosegawa, I., Katayama, S., Kikuchi, C., Kashiwabara, H., Negishi, K., Ishii, J., Inukai, K., & Oka, Y. (1996) · Hypertension Research · doi:10.1291/hypres.19.37 · Cited by 33
Swislocki, A., Eason, T., & Kaysen, G. A. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00161-1 · Cited by 33
Lim, E., Park, S., & Kim, H. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0117-0_13 · Cited by 32
Muntzel, M. S., Abe, A., & Petersen, J. S. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36647-9 · Cited by 31
Oleandri, S. E., Maccario, M., Rossetto, R., Massimo, P., Grottoli, S., Avogadri, E., Gauna, C., Ganzaroli, C., & Ghigo, E. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03350893 · Cited by 30
Stümvoll, M., Häring, H., & Matthaei, S. (2007) · Endocrine Research · doi:10.1080/07435800701743828 · Cited by 31
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Donker, A. J. M., & Stehouwer, C. D. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01554.x · Cited by 30
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 31
Metadata
- Authors
- Giugliano, D., De Rosa, N., Di Maro, G., Marfella, R., Acampora, R., Buoninconti, R., & D'Onofrio, F.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Department of Gerontology and Metabolic Diseases, Second University of Naples Naples, Italy
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1993-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 1387-1390
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2039851346
- Cited by
- 206
- References
- 0
- Citations by year
- 2026: 1 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 9 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 3
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, hypertension, obesity, women, glucose metabolism, insulin sensitivity, blood pressure, left ventricular mass, lipid metabolism, cardiovascular risk, non-diabetic patients, fibrinogen, HDL cholesterol
- MeSH terms
- Blood Glucose, Blood Pressure, Calorimetry, Cholesterol, Double-Blind Method, Echocardiography, Female, Fibrinogen, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Hypertension, Insulin, Metformin, Middle Aged, Obesity, Triglycerides, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
